Perceptions and Knowledge of Cholesterol and Lipid-Lowering Medications Among Treatment-Naive Individuals: A Cross-Sectional Study
- PMID: 40386799
- PMCID: PMC12085121
- DOI: 10.2147/PPA.S511454
Perceptions and Knowledge of Cholesterol and Lipid-Lowering Medications Among Treatment-Naive Individuals: A Cross-Sectional Study
Abstract
Purpose: The literature often includes studies on cholesterol perception and lipid-lowering medication (LLM) use with patients who have used or discontinued LLM for primary or secondary prevention. With the exponential rise in patients needing LLM each year, understanding their knowledge and perceptions of cholesterol and these drugs is crucial. For this reasons, we aimed to determine the perception and knowledge of treatment-naive participants about cholesterol and LLM.
Patients and methods: This cross-sectional study was conducted in Turkey between August 2020 and August 2022. A self-designed online survey developed from literature sources was used to determine the level of knowledge and perception of cholesterol, LLM and influencing factors.
Results: A total of 2062 respondents completed the survey, which was sent to the participants via an online link. The most common sources of information about cholesterol and lipid-lowering medications were medical staff (71%) media (58.4%) and scientific publications (33.3%). The most three common factors affecting the participants' perception of cholesterol and LLM were medical staff (49.6%), media (23.7%), and scientific publications (15.6%).
Conclusion: Our study revealed that participants have some inaccurate and incomplete information about cholesterol and LLM. Medical staff and the media emerged as the primary sources of information and crucial influences on most participants' perceptions of cholesterol and LLM.
Keywords: hypercholesterolemia; illness perception; lipid-lowering medication; medication adherence; non-compliance; statins.
© 2025 Kök et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Similar articles
-
Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study.BMC Public Health. 2022 Feb 4;22(1):228. doi: 10.1186/s12889-022-12595-1. BMC Public Health. 2022. PMID: 35120488 Free PMC article.
-
Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions.Cardiovasc Drugs Ther. 2004 Nov;18(6):475-81. doi: 10.1007/s10557-004-6225-z. Cardiovasc Drugs Ther. 2004. PMID: 15770435 Clinical Trial.
-
Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.Eur J Clin Pharmacol. 2015 Oct;71(10):1245-54. doi: 10.1007/s00228-015-1907-y. Epub 2015 Jul 31. Eur J Clin Pharmacol. 2015. PMID: 26227068
-
Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. Report No.: 14-05204-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. Report No.: 14-05204-EF-1. PMID: 27559550 Free Books & Documents. Review.
-
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. Report No.: 14-05204-EF-2. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. Report No.: 14-05204-EF-2. PMID: 27559556 Free Books & Documents. Review.
References
-
- World Health Organization. Global status report on noncommunicable diseases. Geneva: World Health Organization; 2010. Available from: http://www.who.int/nmh/publications/ncd_report2010/en/. Accessed May 10, 2025.
LinkOut - more resources
Full Text Sources